Comparative Pharmacology
Head-to-head clinical analysis: DARIFENACIN versus ENABLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARIFENACIN versus ENABLEX.
DARIFENACIN vs ENABLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3 subtypes), reducing detrusor muscle contractility.
Darifenacin is a competitive muscarinic receptor antagonist with high affinity for the M3 receptor subtype, which is involved in urinary bladder contraction and salivary secretion. It reduces detrusor muscle overactivity by blocking acetylcholine binding at muscarinic receptors in the bladder.
7.5 mg to 15 mg orally once daily
7.5 mg to 15 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 13-19 hours in young adults, increasing to about 17 hours in elderly; supports once-daily dosing.
Clinical Note
moderateDarifenacin + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Darifenacin."
Clinical Note
moderateDarifenacin + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Darifenacin."
Clinical Note
moderateDarifenacin + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Darifenacin."
Clinical Note
moderateDarifenacin + Fluconazole
13 hours; steady-state achieved within 3-5 days
Approximately 60% of the dose is excreted renally (as metabolites, primarily 3-hydroxydarifenacin) and 40% fecally; less than 3% excreted unchanged.
Renal (70% as metabolites, <1% unchanged), fecal (20%)
Category C
Category C
Antimuscarinic
Antimuscarinic
"The metabolism of Fluconazole can be decreased when combined with Darifenacin."